Rosas-Carrasco Ó, García-Peña C, Sánchez-García S, Vargas-Alarcón G, Gutiérrez-Robledo LM, Juárez-Cedillo T

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 564-573
Archivo PDF: 152.64 Kb.

RESUMEN

Antecedentes. El aumento de las interacciones potenciales fármaco-fármaco (potenciales DDI) es una consecuencia que los adultos mayores experimentan por un mayor número de medicamentos prescritos para una creciente variedad de enfermedades. Este incremento podría estar asociado con muerte hospitalaria. Objetivo. Determinar si existe asociación entre la presencia de potenciales DDI y muerte hospitalaria en adultos mayores, así como describir la frecuencia de las potenciales DDI y caracterizar a los fármacos prescritos. Material y métodos. Estudio retrospectivo mediante la revisión de expedientes de pacientes de 60 años o más que fueron ingresados en un hospital de segundo nivel. Las potenciales DDI fueron identificadas a través del programa Micromedex®. La comorbilidad se clasificó con el Índice de Charlson (ICC). Otras variables como el sexo, edad, número, tipo de fármaco, tipo de interacción y duración de la estancia hospitalaria fueron evaluados. Resultados. 505 pacientes fueron incluidos, entre los cuales 62.77% presentaron al menos un tipo de potenciales DDI. El 15.25% de las interacciones moderadas se deben a la utilización combinada de inhibidores de la enzima convertidora de angiotensina con diuréticos de asa. Entre las interacciones graves, 14.92% se debió a la utilización combinada de fluroquinolonas con hipoglucemiantes. La duración de la estancia, alta comorbilidad, presencia de tres o más interacciones y mayor tiempo de exposición a la interacción, se asociaron, independientemente, con muerte hospitalaria. Conclusiones. La presencia de potenciales DDI en adultos mayores es frecuente y puede estar implicada en la causa de muerte en estos pacientes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004; 13: 306-14.

2. Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. J Clin Pharm Therap 2008; 33: 141-51.

3. Lowe CJ, Raynor DK, Purvis J, Farrin A, Hudson J. Effects of a medicine review and education programme for older people in general practice. Br J Clin Pharmacol 2000; 50: 172-5.

4. Doubova SV, Torres-Arreola LP, Rosas-Carrasco O, Pérez- Cuevas R. Quality of medication prescribing for elderly patients with non-malignant pain syndrome attending family medicine clinics. Rev Invest Clin 2007; 59: 428-36.

5. Radosevic N, Gantumur M, Vlahovic-Palcevski V. Potentially inappropriate prescribing to hospitalized patients. Pharmacoepidemiol Drug Saf 2008; 17: 733-7.

6. Peral AJ, Lertxundi EU, Martínez BMJ Prospective assessment of drug interactions in hospitalized patients using a computer programme. Farm Hosp 2007; 31: 93-100.

7. Lima RE, De Bortoli CSH. Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem 2009; 17: 222-7.

8. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 1996; 14: 447-50.

9. Nixdorff N, Hustey FM, Brady AK, Vaji K, Leonard M, Messinger- Rapport BJ. Potentially inappropriate medications and adverse drug effects in elders in the ED. Am J Emerg Med 2008; 26: 697-70.

10. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalizations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 2007; 16: 641-51.

11. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalization and mortality: a population-based study of the very old. Drugs Aging 2005; 22: 69-82.

12. Hanlon JT, Fillenbaum GG, Kuchibhatla M, Artz MB, Boult C, Gross CR, et al. Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders. Med Care 2002; 40: 166-76.

13. Espino DV, Bazaldua OV, Palmer RF, Mouton CP, Parchman ML, Miles TP, et al. Suboptimal medication use and mortality in an older adult community-based cohort: results from the Hispanic EPESE Study. J Gerontol A Biol Sci Med Sci 2006; 61: 170-5.

14. Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a Department of Internal Medicine. Arch Intern Med 2001; 161: 2317-23.

15. Implementation of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD- 10). Epidemiol Bull 1997; 18: 1-4.

16. WHO. Collaborating Centre for Drug Statistics Methodology: About the ATC/DDD system. Available from: http://www.whocc.no/atcddd/ [Accessed 18 September 2009].

17. Micromedex and Drogas- Reax. Available from: http:// www.micromedex.com [Accessed 18 September 2009].

18. Charlson M, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83.

19. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075-9; discussion 1081-90.

20. SPSS. SPSS for Windows, Version 13. Chicago, IL: SPSS, 2001.

21. Peral J, Lertxundi EU, Martínez BMJ. Prospective assessment of drug interactions in hospitalized patients using a computer programme. Farm Hosp 2007; 31: 93-100.

22. Vonbach P, Dubied A, Krähenbühl S, Beer JH. Prevalence of drug-drug interactions at hospital entry and during hospital stay of patients in internal medicine. Eur J Intern Med 2008; 19: 413-20.

23. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-8.

24. Davies MK, Gibbs CR, Lip GY. ABC of heart failure. Management: diuretics, ACE inhibitors, and nitrates. BMJ 2000; 320: 428-31.

25. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004; 24: 1807-12.

26. Garber SM, Pound MW, Miller SM. Hypoglycemia associated with the use of levofloxacin. Am J Health Syst Pharm 2009; 66: 1014-19.

27. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (Consensus II). Am J Cardiol 1997; 79: 115-19.

28. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33: 1920-5.

29. Peterson JG, Laur MS, Young JB, et al. Evidence for an adverse interaction between ACE inhibitors and aspirin following myocardial infarction: the GUSTO-I Trial. J Am Coll Cardiol 1998 (Suppl. A): 96A.

30. EMPS. Agencia española de medicamentos y productos sanitarios. Disponible en: http://www.aemps.es/actividad/notaMensual/ 2010/mayo2010/nota_medicamentos.htm [Accesed 9 January 2010].

31. Cruciol-Souza JM, Thomson JC. Prevalence of potential drugdrug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 2006; 9: 427-33.

32. Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci 2009; 12: 266-72.

33. Klarin I, Wimo A, Fastbom J. The association of inappropriate drug use with hospitalization and mortality: a population- based study of the very old. Drugs Aging 2005; 22: 69-82.

34. Terleira A, Portoles A, Rojas A, Vargas E. Effect of drug-test interactions on length of hospital stay. Pharmacoepidemiol Drug Saf 2007; 16: 39-45.

35. Farmacovigilancia Instituto Mexicano del Seguro Social (IMSS). Disponible en: http://www imss.gob.mx/transparencia/ cuadros/farmacovigilancia/organizacion [Accessed: 26 October 2009].